MX2022005813A - Formas de dosificacion novedosas de rofecoxib y métodos relacionados. - Google Patents
Formas de dosificacion novedosas de rofecoxib y métodos relacionados.Info
- Publication number
- MX2022005813A MX2022005813A MX2022005813A MX2022005813A MX2022005813A MX 2022005813 A MX2022005813 A MX 2022005813A MX 2022005813 A MX2022005813 A MX 2022005813A MX 2022005813 A MX2022005813 A MX 2022005813A MX 2022005813 A MX2022005813 A MX 2022005813A
- Authority
- MX
- Mexico
- Prior art keywords
- rofecoxib
- dosage forms
- related methods
- novel dosage
- novel
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000371 rofecoxib Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934898P | 2019-11-13 | 2019-11-13 | |
| US202063018136P | 2020-04-30 | 2020-04-30 | |
| US16/867,514 US10945992B1 (en) | 2019-11-13 | 2020-05-05 | Dosage forms of rofecoxib and related methods |
| PCT/US2020/060152 WO2021097038A1 (en) | 2019-11-13 | 2020-11-12 | Novel dosage forms of rofecoxib and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005813A true MX2022005813A (es) | 2022-08-16 |
Family
ID=74870322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005813A MX2022005813A (es) | 2019-11-13 | 2020-11-12 | Formas de dosificacion novedosas de rofecoxib y métodos relacionados. |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10945992B1 (enExample) |
| EP (1) | EP4058012A1 (enExample) |
| JP (1) | JP2023502941A (enExample) |
| KR (1) | KR20220123224A (enExample) |
| CN (1) | CN115605197A (enExample) |
| CA (1) | CA3155900A1 (enExample) |
| MX (1) | MX2022005813A (enExample) |
| TW (1) | TW202128144A (enExample) |
| WO (1) | WO2021097038A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7291220B2 (ja) | 2018-11-21 | 2023-06-14 | トレモ― ファーマシューティカルズ，インコーポレーテッド | ロフェコキシブの精製形態、製造方法および使用 |
| US20200323813A1 (en) * | 2019-04-09 | 2020-10-15 | Tremeau Pharmaceuticals, Inc. | Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal anti-inflammatory drugs |
| US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
| WO2023059698A1 (en) * | 2021-10-06 | 2023-04-13 | Tremeau Pharmaceuticals, Inc. | Methods and compositions for treating von willebrand's migraine disorder |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21647A (en) | 1858-10-05 | Construction of animal-traps | ||
| US21042A (en) | 1858-07-27 | yerby | ||
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| MY119407A (en) | 1993-06-24 | 2005-05-31 | Merck Frosst Canada Inc | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor. |
| CA2180651A1 (en) | 1994-01-10 | 1995-07-13 | Yves Ducharme | Phenyl heterocycles as cox-2 inhibitors |
| US5585504A (en) | 1994-09-16 | 1996-12-17 | Merck & Co., Inc. | Process of making cox-2 inhibitors having a lactone bridge |
| US5849943A (en) | 1994-10-27 | 1998-12-15 | Merck Frosst Canada, Inc. | Stilbene derivatives useful as cyclooxygenase-2 inhibitors |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| BR9709097A (pt) | 1996-05-17 | 1999-08-03 | Merck & Co Inc | Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária |
| GB9615867D0 (en) | 1996-07-03 | 1996-09-11 | Merck & Co Inc | Process of preparing phenyl heterocycles useful as cox-2 inhibitors |
| CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| JP4659190B2 (ja) | 2000-08-31 | 2011-03-30 | アンリツ株式会社 | 波形測定装置 |
| US20040186155A1 (en) * | 2003-01-30 | 2004-09-23 | Dayno Jeffrey Marc | Combination therapy for the treatment or prevention of migraine |
| ES2214129B1 (es) | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 3-fenilfuran-2-onas. |
| EP1646381A4 (en) * | 2003-07-02 | 2009-12-09 | Merck & Co Inc | COMBINATION THERAPY FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES |
| AU2003263582A1 (en) | 2003-08-14 | 2005-03-07 | Shasun Chemicals And Drugs Limited | Process for the manufacture of rofecoxib |
| TR200301552A1 (tr) | 2003-09-18 | 2005-10-21 | Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Rofekoksib' in yeni oral farmakolojik formülasyonları. |
| WO2015066302A2 (en) * | 2013-10-30 | 2015-05-07 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions, methods of use, and methods of treatment |
| CN104173359B (zh) * | 2014-09-05 | 2017-05-03 | 罗国安 | 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用 |
| WO2016089893A1 (en) * | 2014-12-01 | 2016-06-09 | Achelios Therapeutics Inc. | Methods and compositions for treating migraine and conditions associated with pain |
| WO2019193417A1 (en) | 2018-04-05 | 2019-10-10 | Kossen Co., Ltd. | Composition and method of reducing joint pain associated with hemarthrosis |
| JP7291220B2 (ja) * | 2018-11-21 | 2023-06-14 | トレモ― ファーマシューティカルズ，インコーポレーテッド | ロフェコキシブの精製形態、製造方法および使用 |
-
2020
- 2020-05-05 US US16/867,514 patent/US10945992B1/en active Active
- 2020-11-12 KR KR1020227019672A patent/KR20220123224A/ko not_active Withdrawn
- 2020-11-12 WO PCT/US2020/060152 patent/WO2021097038A1/en not_active Ceased
- 2020-11-12 CA CA3155900A patent/CA3155900A1/en active Pending
- 2020-11-12 CN CN202080092241.7A patent/CN115605197A/zh active Pending
- 2020-11-12 TW TW109139523A patent/TW202128144A/zh unknown
- 2020-11-12 EP EP20820012.1A patent/EP4058012A1/en not_active Withdrawn
- 2020-11-12 MX MX2022005813A patent/MX2022005813A/es unknown
- 2020-11-12 JP JP2022528029A patent/JP2023502941A/ja active Pending
- 2020-12-18 US US17/127,970 patent/US20210137878A1/en not_active Abandoned
-
2021
- 2021-02-23 US US17/182,728 patent/US20210169845A1/en not_active Abandoned
- 2021-10-28 US US17/513,281 patent/US20220047542A1/en not_active Abandoned
-
2022
- 2022-06-30 US US17/855,604 patent/US20220409575A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220409575A1 (en) | 2022-12-29 |
| JP2023502941A (ja) | 2023-01-26 |
| EP4058012A1 (en) | 2022-09-21 |
| WO2021097038A1 (en) | 2021-05-20 |
| TW202128144A (zh) | 2021-08-01 |
| US20210137878A1 (en) | 2021-05-13 |
| CA3155900A1 (en) | 2021-05-20 |
| US10945992B1 (en) | 2021-03-16 |
| KR20220123224A (ko) | 2022-09-06 |
| US20210169845A1 (en) | 2021-06-10 |
| CN115605197A (zh) | 2023-01-13 |
| US20220047542A1 (en) | 2022-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005813A (es) | Formas de dosificacion novedosas de rofecoxib y métodos relacionados. | |
| GB2595776B (en) | Therapeutic solid dosage forms | |
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| EP4302835A3 (en) | Methods of treating ovarian cancer | |
| CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
| PH12018501001A1 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| MX2017006454A (es) | Administracion sublingual de riluzol. | |
| PH12020550616A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения | |
| IL281166A (en) | Methods for using the phenoxypropylamine compound to treat pain | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| IL289338B1 (en) | Therapeutic interactions of leucomethylthioninium | |
| BR112022008856A2 (pt) | Terapia combinada para doenças musculares | |
| PH12020500045A1 (en) | Novel composition of enzalutamide oral dosage form and method of manufacturing thereof | |
| JOP20230099A1 (ar) | تركيبات صيدلية | |
| MX2017006205A (es) | Tratamiento de la intoleracia a la alimentacion enteral. | |
| JOP20200104A1 (ar) | مركبات مثبطة لـ btk | |
| MX2021003302A (es) | Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez. | |
| GB201812861D0 (en) | Methods of administering therapy | |
| MX387059B (es) | Compuestos de benzo-n-hidroxi amida que tienen actividad antitumoral. | |
| MX2021007224A (es) | Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas. |